What's Happening?
On April 2, 2026, President Trump signed an executive order that enacts a 100% ad valorem tariff on patented pharmaceutical products and their active pharmaceutical ingredients (APIs). This order, issued under Section 232 of the Trade Expansion Act of 1962,
will take effect on July 31, 2026, for large companies and September 29, 2026, for smaller manufacturers. The tariffs apply to all countries not listed in the proclamation's preferential tiers, which include the EU, Japan, South Korea, Switzerland/Liechtenstein, and the U.K. Generic pharmaceuticals, biosimilars, and certain specialty products are currently exempt, with a review of generics mandated within a year.
Why It's Important?
The imposition of these tariffs represents a significant shift in U.S. trade policy, particularly affecting the pharmaceutical industry. The tariffs are expected to impact drug prices and supply chains, potentially leading to increased costs for consumers and healthcare providers. The executive order aims to bolster national security and strengthen U.S. supply chains by encouraging domestic production. However, it also poses challenges for international pharmaceutical companies and could lead to trade tensions with countries not included in the preferential tiers. The policy is part of a broader strategy to increase domestic investment, with reports of $400 billion in new commitments already triggered by Section 232 pressure.
What's Next?
Pharmaceutical companies must assess their tariff exposure and consider strategic adjustments to their supply chains. Companies with a Most Favored Nation (MFN) pricing agreement or an approved onshoring plan may benefit from reduced tariffs. The transitional 20% onshoring rate will escalate to 100% by April 2, 2030, prompting companies to secure U.S. manufacturing capacity. The industry will need to navigate these changes while balancing compliance with operational efficiency. The executive order's impact on drug development and pricing will be closely monitored by stakeholders across the healthcare sector.
